Skip to main content
Fig. 6 | BMC Genomics

Fig. 6

From: Prioritization of risk genes in multiple sclerosis by a refined Bayesian framework followed by tissue-specificity and cell type feature assessment

Fig. 6

CMap drug signatures enriched in the MS-PRGenes depict potential drug repositioning strategies. (A, B) Drugs enriched for the MS-PRGenes are shown on the y-axis. Enrichment scores represent -log2 (false discovery rate), as reported by the Cogena R package. The color is proportional to the enrichment score. (A) Drugs listed on the y-axis show the enrichment in the drug signatures of downregulated 100 CMap gene set. (B) Drugs show the enrichment from the drug signatures of upregulated 100 CMap gene set

Back to article page

BMC Genomics

ISSN: 1471-2164

Contact us